Reported Earlier, LakeShore Biopharma Takes Decisive Action In Response To Criminal Allegations Against Former Chairman, Yi Zhang
Reported Earlier, LakeShore Biopharma Takes Decisive Action In Response To Criminal Allegations Against Former Chairman, Yi Zhang
Investigation Details: The Company has uncovered evidence suggesting that Yi Zhang, during his tenure in key executive roles, misappropriated corporate assets for personal gain and mismanaged the Company, resulting in significant financial losses over past several years, thereby seriously harming the interests of shareholders of the Company.
调查细节：公司已发现证据，表明在关键管理岗位上任职期间，张益挪用公司资产以谋取个人利益，并对公司进行失职管理，导致过去几年出现重大财务损失，从而严重损害了公司股东的利益。
Corrective Actions: In response to these revelations, by March 2024, the Company took decisive action to remove Yi Zhang from all executive positions within the Company and its subsidiaries, in accordance with the Company's Memorandum and Articles of Association effective at that time and relevant laws. This action was necessary to mitigate the damage caused by Yi Zhang and his associates. Under the new leadership, the Company's financial and operational performance has seen a marked improvement. The Company has achieved smooth operations, secured second position in China's Rabies vaccine market and reaffirmed the full year financial guidance through Fiscal Year 2025 ended March 31, 2025.
纠正措施：针对这些揭露，到2024年3月，公司采取果断行动，将张益从公司及其子公司的所有管理职位中解除，遵循当时有效的公司章程和相关法律。这一行动对于减轻张益及其同伙造成的损害是必要的。在新领导下，公司财务和运营表现明显改善。公司已实现平稳运营，在中国生物-疫苗市场中 secured 了第二的位置，并通过截至2025年3月31日的2025财年确认全年财务指导。
